GH Research PLC
NASDAQ:GHRSBiotechnology
-$0.04 today
- Market cap
- $1.25B
- Beta
- 1.31
- P/E (TTM)
- -23.8
- EPS (TTM)
- -$0.91
Volume 0.46M
Average 0.23M
GHRS Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
GH Research PLCNASDAQ: GHRS
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development growth accelerates
Q1 FY2026 research & development of $12.38M rose 57.7% year over year, ahead of the +26.5% change in trailing-twelve-month research & development. Sequentially, it rose 8.8% from the prior quarter. Over 3 fiscal years it compounded at +23.7% a year.
Context
- Research & development increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +57.7% holds above the trailing-twelve-month pace of +26.5%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 38.73M USD
- Year-over-year change
- +10.6%
- 4-year CAGR
- +45.9%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 38.73M | +10.6% |
| FY2024 | 2024-12-31 | 35.02M | +17.4% |
| FY2023 | 2023-12-31 | 29.82M | +45.6% |
| FY2022 | 2022-12-31 | 20.48M | +139.5% |
| FY2021 | 2021-12-31 | 8.55M | — |
Research & Development vs competitors
How GHRS compares with its peers on the latest reported figures
- GHRS's LTM Mar 2026 research & development of $43.27M is the 8th highest of the 9 companies compared; the peer median is $166.16M.
- Its year-over-year change of +26.5% is the 5th highest of 8, against a peer median of +58.7%.
- Over three fiscal years its annual growth of +23.7% compares with a peer median of +36.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $5.27B | +80515.8% | -26.7% | — | |
| LTM Jun 2026 | $467.76M | -32.9% | +13.3% | — | |
| LTM Mar 2026 | $171.97M | +136.8% | +73.1% | — | |
DFTXDefinium Therapeutics, Inc. | LTM Sep 2026 | $169.81M | +60.3% | +48.2% | — |
NMRANeumora Therapeutics, Inc. Common Stock | LTM Mar 2026 | $162.51M | -21.6% | +18.9% | — |
RAPPRapport Therapeutics, Inc. Common Stock | LTM Mar 2026 | $107.93M | +58.7% | +118.3% | 539.7% |
| LTM Mar 2026 | $55.94M | +19.0% | +24.4% | — | |
| LTM Mar 2026 | $43.27M | +26.5% | +23.7% | — | |
LBRXLB Pharmaceuticals Inc Common Stock | LTM Mar 2026 | $28.47M | — | +131.7% | — |
SPTXSeaport Therapeutics, Inc. Common Stock | — | — | — | — | — |
| Peer median (excluding GHRS) | $166.16M | +58.7% | +36.3% | 539.7% | |
Competitors are the stored peer set for GHRS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 335K |
| Gross Profit | 0 | 0 | 0 | 0 | (335K) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 8.55M | 20.48M | 29.82M | 35.02M | 38.73M |
| Selling, General & Admin | 6.54M | 10.06M | 11.12M | 15M | 21.61M |
| Operating Expenses | 15.1M | 30.55M | 41.22M | 50.31M | 60.34M |
| Depreciation & Amortization | 19K | 47K | 315K | 315K | 335K |
| EBITDA | (9.17M) | (22.41M) | (35.21M) | (38.6M) | (47.46M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (15.1M) | (30.55M) | (41.22M) | (50.31M) | (60.68M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 9 | 858K | 1.89M | 2.63M | 2.63M |
| Interest Expense | 9K | — | 723K | 717K | 463K |
| Other Income / Expenses | 5.9M | 8.1M | 5.64M | 11.35M | 12.42M |
| Income Before Tax | (9.2M) | (22.46M) | (35.59M) | (38.96M) | (48.26M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (9.2M) | (22.46M) | (35.59M) | (38.96M) | (48.26M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (0.18) | (0.14) | (0.68) | (0.75) | (0.79) |
| EPS (Diluted) | (0.18) | (0.14) | (0.68) | (0.75) | (0.79) |
| Weighted Avg Shares | 52.02M | 52.02M | 52.02M | 52.03M | 61.04M |
| Weighted Avg Shares (Diluted) | 52.02M | 52.02M | 52.02M | 52.03M | 61.04M |
GH Research PLC
NASDAQ:GHRS
Intrinsic Alpha fair value
Locked
Current Price
$18.25
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.